A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
第1相
完了
NCT04958252
| 対象疾患 | Healthy |
|---|
| 相 | 第1相 |
|---|
| スポンサー | Boehringer Ingelheim |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 56 名 |
|---|
| 介入（薬剤） | BI 1569912 |
|---|
| 開始日 | 2021年8月5日 |
|---|
| 完了日 | 2023年10月30日 |
|---|
| 結果公開日 | 2026年5月22日 |
|---|
概要
The main objectives of this trial are to investigate safety and tolerability of BI 1569912 in healthy male Japanese subjects following oral administration of single rising doses and multiple doses. Secondary objective is the exploration of pharmacokinetics (PK) of BI 1569912.
SRD Part - Number of Subjects With Drug-related Adverse Events
From drug administration plus 48 hours (residual effect period (REP)), or 12:00 a.m. on day after subject's trial termination date, whichever occurs first, up to 48 hours. · Participants
| SRD Part - Placebo | 0 Participants |
|---|
| Single-rising Dose Part - BI 1569912 2.5 mg | 0 Participants |
|---|
| Single-rising Dose Part - BI 1569912 5 mg | 0 Participants |
|---|
| Single-rising Dose Part - BI 1569912 10 mg | 0 Participants |
|---|
| Single-rising Dose Part - BI 1569912 20 mg | 0 Participants |
|---|
MD Part - Number of Subjects With Drug-related Adverse Events
From first drug administration until last administration of study drug plus 48 hours (REP), or 12:00 a.m. on day after subject's trial termination date, whichever occurs first, up to 16 days. · Participants
| Multiple Dose Part - Placebo | 1 Participants |
|---|
| Multiple Dose Part - 20 mg BI 1569912 | 2 Participants |
|---|
Evening PK Part - Area Under the Concentration-time Curve of BI 1569912 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Within 3 hours (h) prior to drug administration and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 h after drug administration. · hours*nanomole/Liter
| Evening Pharmacokinetics Part - 5 mg BI 1569912 R | 892.68 ± NA hours*nanomole/Liter |
|---|
| Evening Pharmacokinetics Part - 5 mg BI 1569912 T | 817.93 ± NA hours*nanomole/Liter |
|---|
| Ratio of adjusted geometric means [%] | 91.63 (95% CI 89.46–93.84) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。